Join FibroGen, Inc. (#FGEN) for Part II of a virtual KOL investor event series on Wed. June 26 at 10am et featuring Rahul Aggarwal, MD (University of California San Francisco), who will discuss the unmet need and evolving treatment landscape for prostate cancer, as well as the clinical development program for FG-3246, a CD46 targeting antibody-drug conjugate (ADC) with first-in-class potential for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Register here: https://bit.ly/45zUaMl
LifeSci Advisors, LLC
Financial Services
New York, New York 14,682 followers
Accelerating Innovations In Life Science.
About us
LifeSci Advisors is a unique investor relations consultancy founded to provide companies in the life sciences field with a comprehensive solution to investor communications and outreach. Our services are designed to increase our clients’ visibility within the investment community and to educate investors about the opportunity. We strive to effectively communicate each clients’ unique value proposition, building momentum for the investment. We begin with deep due diligence as we partner with each client to gain an unparalleled level of understanding of their business and the opportunities they are addressing. This in-depth knowledge allows us to be able to provide each client partner with thoughtful recommendations related to corporate communications, investor outreach, and capital markets planning. Our strategies and actions are specifically tailored to help each client achieve their investor relations goals.
- Website
-
http://www.lifesciadvisors.com
External link for LifeSci Advisors, LLC
- Industry
- Financial Services
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2009
- Specialties
- Investor Relations
Locations
-
Primary
Get directions
250 W 55th St
#3401
New York, New York 10019, US
Employees at LifeSci Advisors, LLC
Updates
-
Join us this Wednesday, June 26 at 1pm ET for the latest in our "Lunch with LifeSci" series, where we will interview Todd Davis, CEO of Ligand Pharmaceuticals (#LGND) to get an inside look at the biopharmaceutical royalty aggregator and its impressive portfolio. Register now: https://bit.ly/3xw9Ao2
-
-
Join Brainomix for a virtual KOL event on Mon. June 24 at 10am ET featuring Dr. Waleed Brinjikji, M.D. (Mayo Clinic), who will join company leadership to provide a detailed look at the Brainomix 360 Stroke platform, an FDA-cleared and CE-marked collection of tools that use state-of-the-art AI algorithms to provide real-time interpretation of brain scans across the full stroke pathway. Register here: https://lnkd.in/eqaK3PBD
-
-
Join Arrowhead Pharmaceuticals (#ARWR) for Part II of its summer series of R&D webinars on Tues. June 25 at 2pm ET featuring Christie M. Ballantyne, MD, FACP, FACC (Baylor College of Medicine), including updates on two of its key cardiometabolic programs: plozasiran and zodasiran. Register here: https://bit.ly/4bZMdSP
-
-
Don't miss it! R1 RCM is hosting a virtual investor event on Thurs. June 27 at 11 am ET featuring Steven Albert and Brian Gambs. Register here: https://lnkd.in/gmJaY_CA
Join R1 RCM for a virtual investor event on Thurs. June 27 at 11 am ET featuring Steven Albert, Executive Vice President and Chief Product Officer, and Brian Gambs, Executive Vice President and Chief Technology Officer, who will provide an overview of the R1 Platform and key areas of innovation. The event will highlight key advantages of the platform, new AI innovation, and select focus areas of R1’s future technology roadmap. Register here: https://lnkd.in/gmJaY_CA #RCM #Technology #RevenueCycle
-
-
Join X4 Pharmaceuticals for a virtual investor day on Thurs. June 27 at 8am ET, featuring Peter E. Newburger, MD (UMass Chan Medical School) and Jean Donadieu, MD, PhD (Trousseau Hospital, Paris). Register here: https://lnkd.in/eVPTy9Mb
Don't forget to register for our June 27th virtual investor event where we will review new clinical data on our lead product candidate from our ongoing Phase 2 trial in #ChronicNeutropenia. We are excited to include renowned experts Dr. Jean Donadieu, MD, PhD, and Dr. Peter E. Newburger, MD, who will share their insights on the interim results and the high unmet need in CN. Register now by clicking the link here: https://bit.ly/3VuyTQu #Progress4Patients
-
-
LifeSci Advisors, LLC reposted this
Exciting events ahead! Don’t miss these in-depth discussions focused on a variety of therapeutic areas, including neurology, immunology, and oncology. Gain invaluable insights from industry leaders and broaden your expertise. Secure your spot today at https://lnkd.in/eSAFbsXv. #LifeSciEvents #KOLEvents #Biotech Orchestra BioMed UroGen Pharma Ocular Therapeutix, Inc. Shattuck Labs PolyPid Ltd. Helio Genomics BioInvent International AB Milestone Pharmaceuticals, Inc. Protalix Biotherapeutics R1 RCM Nusano
-
-
We’re very pleased to announce today that Chris Howerton, Ph.D. has joined LifeSci Advisors on the IR Communications team. Chris has a great background, having been a well-respected sell side analyst, senior manager in industry and academic researcher. He is very well qualified to advise our clients on communication and investor strategy. For more information, please refer to the press release here: https://bit.ly/4cm3F3V
-
-
Join Protalix Biotherapeutics (#PLX) for an in-person investor day in New York on Mon. June 26 at 8:30am ET featuring Aleš Linhart, DSc, FESC (Charles University, Prague) and Naomi Schlesinger, MD (University of Utah), who will discuss the current treatment landscapes and clinical results for fabry disease and uncontrolled gout. Register here: https://bit.ly/3KA5GO7
-
-
Join Sagimet Biosciences (#SGMT) for a conference call and webcast on Thurs. June 13 at 12:30pm ET featuring Rohit Loomba, M.D., https://bit.ly/3jySxqf., (MASLD Research Center, University of California San Diego), to discuss positive data from the FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. Attend: https://bit.ly/3Vs9Exk
-